CHANGE IN RATINGS
downgraded at Deutsche Bank to Hold from Buy and price target reduced to $30 from $67.
Bank of America
downgraded at Goldman Sachs to Neutral from Buy based on reduced earnings power. Price target lowered to $7 from $35.
Bed, Bath & Beyond
downgraded at JP Morgan from Neutral to Underweight. $20 price target.
downgraded at JP Morgan to Underweight from Neutral. Price target cut to $10 from $20.
upgraded at Wachovia to Outperform from Market Perform. Establishes price target of $20 to $21. Maintains 2009 EPS estimates of $1.77.
downgraded at UBS to Sell from Neutral and price target reduced to $40 from $48.
upgraded at RBC to Sector Perform from Underperform. Maintains $20 price target. Maintains 2009 EPS estimates of $3.80.
downgraded at Piper Jaffray to Sell from Neutral. Price target lowered to $35 from $44. 2009 EPS estimates lowered to $3.27 from $4.40.
upgraded at Citigroup from Hold to Buy.
upgraded at Goldman Sachs to Buy from Neutral. Price target trimmed to $22 from $24.
downgraded at Goldman Sachs to Sell from Neutral. Price target lowered to $12 from $28.
STOCK COMMENTS / EPS CHANGES
numbers cut at UBS. Target lowered to $20. Estimates also lowered ahead of earnings. Buy rating.
numbers lowered at Morgan Stanley through 2010. Domestic market has seen an unexpected slowdown. Overweight rating and new $18 price target.
numbers cut at Morgan Stanley. Shares now seen reaching $20. Estimates also lowered, because of weaker expected order trends. Overweight rating. Cisco estimates cut at UBS through 2010. Neutral rating.
numbers lowered at UBS through 2010. Buy rating and new $14 price target.
numbers cut at Barclays. Shares now seen reaching $14. Estimates also lowered, to reflect the poor economic environment. Equal-weight rating.
numbers cut at Citigroup. 2009 estimate lowered to reflect Capital Services losses. Hold rating and new $12 price target. GE numbers cut at Morgan Stanley through 2010. Overweight rating and new $19 price target. GE price target lowered at Goldman to $13 from $15. Maintained Neutral rating.
estimates lowered at Citigroup through 2010. Buy rating and $65 price target.
St. Jude Medical
numbers raised at UBS. Shares now seen reaching $36. Estimates also increased. Buy rating.
This article was written by a staff member of TheStreet.com.